Found 113 articles for: "Acne"
Early Acne Improvements With Fixed-Combination Topical Therapy: Analysis of the First 4 Weeks of Treatment
January 2025 | Volume 24 | Issue 1 | Journal Article | 79 | Copyright © January 2025
Background: Acne treatment can take weeks to deliver noticeable improvements, which may diminish patients’ perception of treatment effectiveness and undermine treatment adh...
Read MoreUtility of Adding Platelet-Rich Plasma to Microneedling vs Microneedling Alone in the Treatment of Acne Scarring
January 2025 | Volume 24 | Issue 1 | Journal Article | 41 | Copyright © January 2025
Acne vulgaris is one of the most common skin diseases worldwide and affects a large population of patients. Post-acne scarring can pose a significant psychosocial burden on patients of all ages; ...
Read MoreIntegrating Dermocosmetic Therapy for Acne: Addressing Severity Levels in Real-Life Experiences
January 2025 | Volume 24 | Issue 1 | Journal Article | 88 | Copyright © January 2025
Background: Acne is prevalent in approximately 80% of individuals aged 11 to 30 years, with scarring occurring in about 40% of cases. Early and sustained treatment is crucial for...
Read MoreError: 429: HTTP/2 429Laser and Energy Treatments for Acne Scarring: A Review of Clinical Trials
December 2024 | Volume 23 | Issue 12 | | 1058 | Copyright © December 2024
Background: Acne scarring can have a detrimental impact on quality of life, making early and effective treatment essential. Lasers and energy-based treatment are the preferred tr...
Read MoreError: 429: HTTP/2 429Effective With Minimal Side Effects: A Novel Treatment Regimen for Acne Vulgaris Using Multifunctional Ingredients
December 2024 | Volume 23 | Issue 12 | | 1042 | Copyright © December 2024
Background: There are numerous over-the-counter products for treating acne, although many formulations have tolerability issues and lack the cosmetic elegance desired by adult pa...
Read MoreError: 429: HTTP/2 429Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne in Children and Adolescents
December 2024 | Volume 23 | Issue 12 | | 1049 | Copyright © December 2024
Background: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose triple-combination approved for acne (indicated in patients ...
Read MoreError: 429: HTTP/2 429Novel Methods in Acne Treatment and Skin Care: A Review
December 2024 | Volume 23 | Issue 12 | | e181 | Copyright © December 2024
Background: Acne skin care aims to reduce the stratum corneum layer, normalization of sebum secretion, and mitigation of purulent lesions. Antibiotics, such as macrolides, clinda...
Read MoreError: 429: HTTP/2 429Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Participants With Moderate-to-Severe Acne: The Patient Journey
November 2024 | Volume 23 | Issue 11 | | 1017 | Copyright © November 2024
Introduction: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose, triple-combination formulation approved for acne treatmen...
Read MoreError: 429: HTTP/2 429Treatment of Mild to Severe Acne Vulgaris With a 650-Microsecond 1064-nm Nd:YAG Laser
November 2024 | Volume 23 | Issue 11 | | 957 | Copyright © November 2024
Background: Effective treatment of acne remains a challenge to dermatologists.Objective: To evaluate the efficacy and tolerability of a 650-microsec...
Read MoreError: 429: HTTP/2 429Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis
October 2024 | Volume 23 | Issue 10 | | 873 | Copyright © October 2024
Background: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) is the only fixed-dose triple-combination treatment approved for acne. This post hoc analys...
Read MoreError: 429: HTTP/2 429Application Characteristics and Patient Preference of Triple-Combination vs Layered Topicals for Acne: Split-Face Study
October 2024 | Volume 23 | Issue 10 | | 857 | Copyright © October 2024
Background: Although triple-combination therapies for acne are generally more efficacious than dual-combinations or topical monotherapy, this benefit may be offset by reduced adh...
Read MoreError: 429: HTTP/2 429Treatment of Acne Vulgaris-Associated Post-Inflammatory Dyschromia With Combination of Non-Ablative Laser Therapy and Topical Antioxidants
September 2024 | Volume 23 | Issue 9 | | 769 | Copyright © September 2024
Acne can cause disfiguring sequelae, such as scarring, post-inflammatory erythema (PIE), and post-inflammatory hyperpigmentation (PIH). These post-inflammatory dyschromias pose a significant psyc...
Read MoreError: 429: HTTP/2 429To Acne and Beyond: A Review of Sarecycline's Off-Label Uses
September 2024 | Volume 23 | Issue 9 | | 792 | Copyright © September 2024
NECASA I: A Practical Algorithm Integrating Skincare in the Management of Acne Patients in the Nordic European Countries
September 2024 | Volume 23 | Issue 9 | | 782 | Copyright © September 2024
Background: Acne vulgaris is a multifactorial dermatosis primary of the face and trunk. Erythema, pruritus, and xerosis are frequent adverse effects of first-line acne treatment ...
Read MoreError: 429: HTTP/2 429United Arab Emirates Consensus Recommendations for Management of Acne Vulgaris
August 2024 | Volume 23 | Issue 8 | | 653 | Copyright © August 2024
Acne in the United Arab Emirates is a common disease that causes burden to patients, has psychosocial impacts, and is associated with physical sequelae such as dyspigmentation and scarring. This ...
Read MoreError: 429: HTTP/2 429Challenges in Adult Acne and the Role of Skin Care in Managing the Condition
August 2024 | Volume 23 | Issue 8 | | 674 | Copyright © August 2024
Background: Acne vulgaris is a complex, multifactorial, inflammatory skin condition. Although frequently presented at dermatology clinics, the literature on adult acne is scarce,...
Read MoreError: 429: HTTP/2 429An Open-label Study to Investigate the Efficacy and Tolerability of Dapsone Gel, 7.5% in the Treatment of Acne Vulgaris in Men and Women With Skin of Color
June 2024 | Volume 23 | Issue 6 | | 410 | Copyright © June 2024
Introduction: Acne vulgaris is a common skin disease prevalent in skin of color patients. Studies have demonstrated that dapsone gel, 7.5% (Aczone) used once daily is effective, ...
Read MoreError: 429: HTTP/2 429Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne in Adult and Pediatric Participants
June 2024 | Volume 23 | Issue 6 | | 394 | Copyright © June 2024
Background: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) is the first fixed-dose triple-combination approved for the treatment of acne. This...
Read MoreError: 429: HTTP/2 429Investigating the Relationship Between Acne and Vasodilatory Medications in a Hospital-Wide Adult Population
June 2024 | Volume 23 | Issue 6 | | 446 | Copyright © June 2024
Acne vulgaris is a common chronic dermatological condition characterized by obstruction and inflammation of pilosebaceous units. Recent research on a different dermatologic condition has demonstr...
Read MoreError: 429: HTTP/2 429Topical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances
June 2024 | Volume 23 | Issue 6 | | 438 | Copyright © June 2024
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
